Cargando…
Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical d...
Autores principales: | Tan, Peixin, Huang, Wei, He, Xinyan, Lv, Fengquan, Cui, Yanhai, Du, Shasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889196/ https://www.ncbi.nlm.nih.gov/pubmed/36637978 http://dx.doi.org/10.1097/CJI.0000000000000451 |
Ejemplares similares
-
Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
por: Cheng, Jun, et al.
Publicado: (2022) -
Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images
por: Tan, Peixin, et al.
Publicado: (2022) -
Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023) -
Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019) -
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)